Business
Sun Biopharma, Inc. Presents Poster at Pancreasfest in Pittsburgh, Pa.
Sun Biopharma, Inc. Presents Poster at Pancreasfest in Pittsburgh, Pa..
About this update from Panbela Therapeutics, Inc.
[{"type":"text","content":"\n \n Results of Phase 1 Safety Study of SBP-101 for Pancreatic Ductal AdenocarcinomaPancreasFest is an International Conference of Physicians and Scientists Focused on Pancreatic Diseases MINNEAPOLIS, MN, July 27, 2018 (GLOBE NEWSWIRE) -- – Sun BioPharma, Inc. (OTCQB:SNBP) a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic diseases, announced the presentation yesterday of a poster reviewing the results of the Phase 1 Safety Study of its candidate drug, SBP-101, a polyamine metabolic inhibitor for pancreatic ductal adenocarcinoma (PDA) at PancreasFest in Pittsburgh, PA.  PancreasFest is an international meeting of physicians and scientists committed to reporting and sharing research in pancreatic cancer and pancreatitis.  The poster was presented by Michael Walker, M.D., Director of Pancreatic Research for Sun BioPharma. Dr. Walker said, “The conclusion of the study was that SBP-101 was well tolerated at dose levels 1-4 and that a dose of 0.8 mg/kg of body weight exceeded the maximum tolerated dose (MTD).  The best tumor response occurred with 0.2 mg/kg/day.  The low incidence of adverse events below the MTD and absence of drug-related bone marrow toxicity or peripheral neuropathy in these heavily pre-treated PDA patients, suggest the potential for SBP-101 as an addition to front-line treatment for PDA and justify a combination study.” David B. Kaysen, President and CEO of Sun BioPharma said, “PancreasFest is an annual gathering of the top minds in the world focused on diseases of the pancreas, including PDA.  We are very pleased to present our poster at this conference, providing the ability to interface with many of the key leaders in pancreatic cancer.  The study recapped in this poster has laid the groundwork for Sun BioPharma to begin our second clinical study of SBP-101 for PDA.  This new front-line study combining SBP-101 with standard of care chemotherapy for previously untreated metastatic PDA patients is being conducted at the University of Florida and sites in Sydney, Melbourne, and Adelaide, Australia.  The first patients began treatment on June 13, 2018 in Australia and the United States.” About SBP-101SBP-101 is a first-in-class, proprietary, polyamine compound designed...